Clients

Galectin Therapeutics Inc.

Company Snapshot: Galectin Therapeutics Inc.

GALT
Last Change Volume High Low

Company Overview

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.

Featured Documents

Client News

  1. Aug 18 2017 Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
  2. Aug 14 2017 Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
  3. Jul 25 2017 Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics
  4. Jul 7 2017 Galectin Therapeutics to Present at the Singular Research Summer Conference